Previous 10 | Next 10 |
ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today their sponsorship of Donate Life at the annual Tournament of Roses ®...
AxoGen has upcoming clinical trial inflection points that must be considered in addition to sales momentum in the back end of this year. Cost-targeting & liquidity preservation measures taken by management this year have been realised at the level of operating efficiency. The ...
ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at two upcom...
AxoGen, Inc. (AXGN) Q3 2020 Earnings Conference Call October 29, 2020 04:30 PM ET Company Participants Pete Mariani - Chief Financial Officer Karen Zaderej - Chairman, Chief Executive Officer & President Conference Call Participants Raj Denhoy - Jefferies Chris Pasquale - Guggenheim Prese...
Image source: The Motley Fool. AxoGen Inc (NASDAQ: AXGN) Q3 2020 Earnings Call Oct 29, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: AxoGen Inc (AXGN) Q3 2020 Earnings Call Transcript
AxoGen (AXGN): Q3 Non-GAAP EPS of $0.04 beats by $0.18; GAAP EPS of -$0.04 beats by $0.15.Revenue of $33.4M (+16.9% Y/Y) beats by $5.28M.Press Release For further details see: AxoGen EPS beats by $0.18, beats on revenue
ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended September 30, 2020. ...
ALACHUA, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report third quarter 2020 financial results on Thursday, Octob...
COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity. Clinical data for AxoGen's key Avance product remain quite strong, showing equal-to-better efficacy compar...
Healthcare veteran brings 30+ years of medtech experience to Axo g en, Inc. Board of Directors ALACHUA, Fla., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or d...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...